41,615 Shares in Metagenomi, Inc. (NASDAQ:MGX) Purchased by Diametric Capital LP

Diametric Capital LP acquired a new stake in shares of Metagenomi, Inc. (NASDAQ:MGX) in the 4th quarter, HoldingsChannel reports. The firm acquired 41,615 shares of the company’s stock, valued at approximately $150,000.

A number of other hedge funds also recently added to or reduced their stakes in MGX. Rhumbline Advisers increased its holdings in shares of Metagenomi by 123.3% in the fourth quarter. Rhumbline Advisers now owns 11,998 shares of the company’s stock valued at $43,000 after purchasing an additional 6,626 shares during the period. BNP Paribas Financial Markets increased its stake in Metagenomi by 130.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 12,799 shares of the company’s stock valued at $28,000 after buying an additional 7,256 shares during the period. Corebridge Financial Inc. increased its stake in Metagenomi by 303.1% in the 4th quarter. Corebridge Financial Inc. now owns 13,602 shares of the company’s stock valued at $49,000 after buying an additional 10,228 shares during the period. SG Americas Securities LLC purchased a new position in Metagenomi during the 4th quarter worth $43,000. Finally, Virtu Financial LLC acquired a new stake in shares of Metagenomi in the 3rd quarter worth $33,000.

Metagenomi Stock Up 0.8 %

Shares of NASDAQ MGX opened at $1.33 on Thursday. The stock has a market capitalization of $49.72 million and a price-to-earnings ratio of -0.51. Metagenomi, Inc. has a 52 week low of $1.29 and a 52 week high of $10.94. The firm has a 50-day moving average price of $2.16 and a 200 day moving average price of $2.40.

Metagenomi (NASDAQ:MGX) last posted its quarterly earnings results on Monday, March 17th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.01). The company had revenue of $9.61 million for the quarter, compared to analyst estimates of $13.18 million. Metagenomi had a negative net margin of 134.27% and a negative return on equity of 43.23%. During the same quarter in the previous year, the business posted ($20.05) earnings per share. Equities research analysts expect that Metagenomi, Inc. will post -2.46 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on MGX shares. Wells Fargo & Company cut their price target on shares of Metagenomi from $25.00 to $20.00 and set an “overweight” rating for the company in a report on Tuesday, March 18th. HC Wainwright boosted their target price on Metagenomi from $7.00 to $14.00 and gave the stock a “buy” rating in a research report on Tuesday, December 10th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $14.40.

Metagenomi Company Profile

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.